Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 60429-321

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 60429-321). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

60429 321 30lb

Donepezil Hydrochloride 5 mg film-coated tablets label showing 30 tablets per container. The label includes the NDC 60429-321-30 and directions for pharmacists to dispense patient information. Manufactured by ScieGen Pharmaceuticals and marketed by GSMS, Incorporated. The label also indicates storage conditions and child-resistant packaging requirements.*

FDA Label Image

60429 322 30lb

Donepezil Hydrochloride 10 mg film-coated tablets label shows a bottle containing 30 tablets. The label displays the NDC 60429-322-30 and states the active ingredient as 10 mg donepezil hydrochloride, USP. It includes storage instructions, a barcode, and notes that it is Rx only. The manufacturer is ScieGen Pharmaceuticals, Inc., and the labeler is GSMS Incorporated.*

FDA Label Image

Fig.1 (Donepezil Figure 01)

Chemical structure of Donepezil Hydrochloride showing its molecular components including aromatic rings, methoxy groups, and a piperidine ring with the hydrochloride (HCl) moiety.*

FDA Label Image

3 (Donepezil Figure 02)

A line graph depicting ADAS-cog mean change from baseline over 18 weeks of drug treatment, comparing Donepezil Hydrochloride at 10 mg/day, 5 mg/day, and placebo. The vertical axis shows clinical improvement or decline, with baseline in the middle. Error bars indicate variability at each time point.*

FDA Label Image

4 (Donepezil Figure 03)

A cumulative percentage plot showing patient response over changes from baseline in ADAS cognitive scores for Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo groups. The x-axis represents change from baseline, and the y-axis shows cumulative percentage of patients. Data points highlight improvements of 7 points, 4 points, and no change. Included is a table listing treatment groups with percentage of patients achieving specified changes (-7, -4, 0) in ADAS cognition scores.*

FDA Label Image

5 (Donepezil Figure 04)

A bar chart comparing response categories based on the CIBIC-plus rating for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The vertical axis shows the percentage of patients, and the horizontal axis lists response categories from Markedly Improved to Markedly Worse.*

FDA Label Image

6 (Donepezil Figure 05)

A line graph showing ADAS-cog cognitive change from baseline (mean ± SE) over 12 weeks of drug treatment with Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The graph compares clinical improvement and decline, indicating cognitive scores across treatment weeks.*

FDA Label Image

7 (Donepezil Figure 06)

A cumulative percentage of patients line chart showing changes from baseline for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The x-axis represents change from baseline, while the y-axis shows cumulative percentage of patients. A comparison table of treatment groups indicates changes in ADAS cognition scores at various points (-7, -4, 0).*

FDA Label Image

8 (Donepezil Figure 07)

A bar chart comparing the percentage of patients across different CIBIC-plus Rating categories: Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse. Data are shown for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups with distinct bars representing each treatment.*

FDA Label Image

9 (Donepezil Figure 08)

A line graph showing SIB (Severe Impairment Battery) change from baseline over 6 months of drug treatment comparing Donepezil Hydrochloride 10 mg/day and placebo. The y-axis represents mean change from baseline with error bars, indicating clinical improvement above baseline and clinical decline below. Donepezil shows a positive increase, peaking around 3 months and slightly declining at 6 months, while placebo shows a slight decrease over time.*

FDA Label Image

10 (Donepezil Figure 09)

A cumulative percentage of patients chart showing the SIB (Severe Impairment Battery) change from baseline. The x-axis measures SIB change, ranging from about 30 to -75, and the y-axis shows the cumulative percentage of patients from 0 to 100%. Two data series are shown: Donepezil Hydrochloride 10 mg/day represented by filled circles, and Placebo represented by open squares. The chart illustrates the difference in patient response between the Donepezil Hydrochloride group and the Placebo group.*

FDA Label Image

11 (Donepezil Figure 10)

Line graph showing the mean change from baseline (± SE) in ADCS-ADL scores over 6 months of treatment comparing Donepezil Hydrochloride Tablets 10 mg/day versus placebo. The y-axis represents clinical improvement or decline, and the x-axis shows months of drug treatment. Donepezil shows less decline than placebo over time.*

FDA Label Image

18 (Donepezil Figure 11)

A cumulative percentage graph comparing Donepezil Hydrochloride 10 mg/day versus placebo. The x-axis displays ADCS-ADL change from baseline, ranging from 20 to -20, and the y-axis shows cumulative percentage of patients from 0 to 100%. Donepezil shows a higher cumulative percentage of patients with negative changes compared to placebo.*

FDA Label Image

19 (Donepezil Figure 12)

A line graph showing SIB (Severe Impairment Battery) change from baseline (LS mean ±SE) over 24 weeks of drug treatment with Donepezil Hydrochloride at doses of 10 mg/day and 23 mg/day. The graph indicates clinical improvement or decline relative to baseline over time for each dosage group.*

FDA Label Image

20 (Donepezil Figure 13)

A cumulative percentage of patients chart illustrating SIB change from baseline for Donepezil Hydrochloride at dosages of 10 mg/day and 23 mg/day. The horizontal axis represents SIB change from baseline, ranging from +50 to -60, and the vertical axis shows the cumulative percentage of patients from 0 to 100%. Two lines compare the performance of the two dosages.*

FDA Label Image

Donepezil Figure 14

A bar chart comparing the percentage of patients on Donepezil Hydrochloride Tablets at doses of 10 mg/day and 23 mg/day across various CIBIC-plus Rating categories, including Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.